Filing Details
- Accession Number:
- 0001209191-17-048786
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-08-14 17:04:14
- Reporting Period:
- 2017-08-10
- Filing Date:
- 2017-08-14
- Accepted Time:
- 2017-08-14 17:04:14
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1510580 | Kite Pharma Inc. | KITE | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1422772 | Susan Helen Kim | C/O Kite Pharma, Inc. 2225 Colorado Avenue Santa Monica CA 90404 | Evp, Business Development | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-08-10 | 3,595 | $53.90 | 22,259 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2017-08-10 | 2,656 | $51.43 | 24,915 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-08-10 | 6,251 | $120.09 | 18,664 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2017-08-10 | 3,595 | $0.00 | 3,595 | $53.90 |
Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2017-08-10 | 2,656 | $0.00 | 2,656 | $51.43 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
56,407 | 2024-12-14 | No | 4 | M | Direct | |
37,344 | 2025-05-18 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2017.
- 25% of the 180,000 shares subject to the stock option vested and became exercisable on November 10, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- 25% of the 120,000 shares subject to the stock option vested and became exercisable on November 10, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.